Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Insulin detemir (Levemir)].

A J Scheen1, R P Radermecker, J C Philips

  • 1Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine, CHU Sart Tilman, Liège. andre.scheen@chu.ulg.ac.be

Revue Medicale De Liege
|December 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Insulin detemir (Levemir) offers predictable, long-acting glucose control for diabetes patients. It provides consistent effects with less variability and a lower risk of hypoglycemia compared to NPH insulin.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Context:

  • Insulin therapy is crucial for managing diabetes mellitus.
  • Basal insulin analogs aim to provide sustained glycemic control.
  • Insulin detemir represents an advancement in long-acting insulin formulations.

Purpose:

  • To evaluate the pharmacokinetic and pharmacodynamic profile of insulin detemir.
  • To compare the efficacy and safety of insulin detemir with NPH insulin.
  • To assess insulin detemir's role in basal insulin therapy for diabetes.

Summary:

  • Insulin detemir, a long-acting acylated human insulin analogue, binds reversibly to albumin for slow absorption and up to 24-hour effect.
  • It demonstrates predictable, consistent glycemic control with reduced intrapatient variability versus NPH insulin.

Related Experiment Videos

  • Insulin detemir is as effective as NPH insulin, with a lower risk of nocturnal hypoglycemia and less weight gain.

    • Impact:

    • Insulin detemir offers a reliable option for basal insulin therapy, particularly in basal-bolus regimens.
    • Its predictable profile may improve patient adherence and outcomes in type 1 and type 2 diabetes.
    • Reduced hypoglycemia risk and weight gain contribute to improved quality of life for diabetic patients.